Skip to main content

Daurismo Disease Interactions

There are 2 disease interactions with Daurismo (glasdegib).

Moderate

Glasdegib (applies to Daurismo) QT interval prolongation

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Long QT Syndrome, Congestive Heart Failure, Electrolyte Abnormalities

Patients treated with glasdegib can develop QTc prolongation and ventricular arrhythmias, including ventricular fibrillation and ventricular tachycardia. The clinical trial excluded patients with baseline QTc of greater than 470 ms or with a history of long QT syndrome or uncontrolled cardiovascular disease. Monitor electrocardiograms (ECGs) and electrolytes closely in patients under treatment. In patients with congenital long QT syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval, more frequent ECG monitoring is recommended. Interrupt glasdegib if QTc increases to greater than 500 ms, and discontinue permanently for patients who develop QTc interval prolongation with signs or symptoms of life-threatening arrhythmia

References

  1. (2018) "Product Information. Daurismo (glasdegib)." Pfizer U.S. Pharmaceuticals Group
Moderate

Glasdegib (applies to Daurismo) renal/hepatic

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction, Liver Disease

Glasdegib has not been studied in patients with severe renal impairment or moderate-to-severe hepatic impairment. Caution is advised.

References

  1. (2018) "Product Information. Daurismo (glasdegib)." Pfizer U.S. Pharmaceuticals Group

Daurismo drug interactions

There are 432 drug interactions with Daurismo (glasdegib).

Daurismo alcohol/food interactions

There is 1 alcohol/food interaction with Daurismo (glasdegib).

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer